Introduction
============

Ischemic preconditioning (IPC) is a phenomenon in which brief episodes of sublethal ischemia induce robust protection against the deleterious effects of subsequent, prolonged, lethal ischemia ([Fig. 1](#F1){ref-type="fig"}). This phenomenon, initially discovered in the heart by Murry et al. in 1986,^[@B1]^ has been shown to occur in many organ systems, including the brain^[@B2]--[@B4]^ and spinal cord.^[@B5],[@B6]^ Subsequently, IPC has been shown to be neuroprotective using many other stimuli, such as hypoxia, hyperoxia, hypothermia, and anesthetics.^[@B7]^ IPC was initially observed within two time windows. The first window, which is known as the rapid or short-term window, appears minutes after preconditioning and lasts for a few hours. The second window, which is known as the delayed or long-term window, appears within a day of preconditioning and is thought to last for a maximum of 7 days after preconditioning.^[@B7],[@B8]^ More recently, various other procedures called ischemic postconditioning (IPoC), remote ischemic preconditioning (RIPC), remote ischemic perconditioning (RIPerC) and remote ischemic postconditioning (RIPoC) were discovered^[@B6],[@B7]^ ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Schematic illustration of the various types of ischemic tolerance induced by non-lethal ischemia for target organ (e.g. brain, spinal cord). Various methods have been reported to induce tolerance, depending on the timing of non-lethal ischemia. IPC: ischemic preconditioning, IPoC: ischemic postconditioning.](nmc-57-590-g1){#F1}

![Schematic illustration of various types of remote ischemic conditioning. Various timing of non-lethal ischemia for remote organ (e.g. four extremities) have been reported to induce tolerance in target organ (e.g. brain, spinal cord). RIPC: remote ischemic preconditioning, RIPoC: remote ischemic postconditioning, RIPerC: remote ischemic per-conditioning.](nmc-57-590-g2){#F2}

Unlike the ischemic tolerance of the brain, most reports of the ischemic tolerance of the spinal cord have come from cardiovascular surgeons or anesthesiologists, and relate to the prevention of ischemic spinal cord injury during aortic surgery.^[@B5],[@B6],[@B9]^ Consequently, neurosurgeons are considered to be less familiar with ischemic tolerance of the spinal cord; however, neurosurgeons sometimes have opportunities to see patients with spinal cord ischemia, such as in spinal infarction or vascular malformation of the spinal cord. Understanding the ischemic tolerance of the spinal cord is therefore also important for neurosurgeons. In this review article, we focus on summarizing the current knowledge of ischemic tolerance of not only the brain, but also the spinal cord.

The term ischemic tolerance is used in this article to include IPC (a state in which ischemic tolerance is acquired by some treatment before invasive ischemia), IPoC (a state in which ischemic tolerance is acquired by some treatment after invasive ischemia), and IPerC (a state in which ischemic tolerance is obtained by some treatment during invasive ischemia).

History of ischemic preconditioning
-----------------------------------

Mild brain injury made by a small needle at four sites, 1 week before brain ischemia, was demonstrated to increase the number of survivors at 1 week after an ischemic insult in a mouse experimental model. This result by Takahata et al. is considered to be the first report suggesting that anti-ischemic factors are released by the injured brain, or that certain, unknown protective mechanisms against ischemia become active following brain injury.^[@B10]^ The authors speculated that anti-ischemic factors or other unknown protective mechanisms are activated by preconditioning. In 1986, the same year as the Takahata et al. report, Murry et al. observed that four cycles of 5 min of ischemia and reperfusion, prior to a more sustained episode of 40 min of ischemia, considerably reduced myocardial infarction compared with controls.^[@B1]^ This was the first description of an endogenous protective phenomenon called IPC. In 1990, Kitagawa et al. investigated the effects of mild and nonlethal ischemic insult on neuronal death following a subsequent lethal ischemic stress, using a gerbil model of bilateral cerebral ischemia^[@B3]^ ([Table 1](#T1){ref-type="table"}). Two 2 min ischemic treatments at 1-day intervals, 2 days before 5 min of ischemia, afforded complete protection against neuronal death.^[@B3]^ In 1991, Kirino et al. also demonstrated protective effect of 2 min ischemic treatment 1 day, 2 days and 4 days before 5 min of ischemia using a gerbil model of global ischemia.^[@B2]^ They reported that the protective mechanism involves heat-shock proteins induced by very brief ischemia which renders neurons more tolerant to subsequent ischemia.^[@B2]^ As reported by Murry et al.^[@B1]^ ischemic tolerance that develops within a few hours of a brief ischemic load is called early or rapid IPC, and as reported by Kitagawa et al.^[@B3]^ and Kirino et al.^[@B2]^ ischemic tolerance that develops after 24 hours is called delayed IPC ([Fig. 1](#F1){ref-type="fig"}).

###### 

Reported ischemic tolerance in the brain and spinal cord induced by different timings and sites

                          Delayed preconditioning   Rapid preconditioning     Postconditioning                Remote conditioning                                                                                                                         
  ----------------------- ------------------------- ------------------------- ------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- --------------------- --------------------- --
  Brain                   Global ischemia           Kitagawa K 1990^[@B3])^   Perez-Pinzon MA 1997^[@B20])^   Burda J 2006^[@B28])^   Wang JY 2008^[@B14])^                           Zhao HG 2004^[@B54])^                                               
  Kirino T 1991^[@B2])^                                                                                                                                                                                                                                   
  Focal ischemia          Chen J 1995^[@B4])^                                                                 Zhao H 2006^[@B25])^    Ren C 2008^[@B55])^     Hahn CD 2011^[@B12])^   Hahn CD 2011^[@B12])^   Ren C 2009^[@B56])^   Ren C 2009^[@B56])^   
    Spinal cord           Abraham VS 2000^[@B5])^   Kakimoto M 2003^[@B6])^                                                                                   Dong HL 2010^[@B57])^                                                                       

More recently, various methods to induce ischemic tolerance have been discovered that depend on the timing and site at which short-term ischemia occurs. In 1993, RIPC was reported in the myocardium.^[@B11]^ RIPC is a phenomenon in which increased tolerance to an ischemic insult is induced after a short-term ischemia/reperfusion episode in a distant body tissue or organ, and was also demonstrated to be protective for cerebral ischemia in 2011^[@B12]^ ([Fig. 2](#F2){ref-type="fig"}). Furthermore, IPoC, which consists of brief ischemia applied during the onset of reperfusion, was reported to be cardioprotective,^[@B13]^ and has subsequently been shown to also be effective against cerebral ischemia1^[@B14],[@B15]^ ([Fig. 1](#F1){ref-type="fig"}).

Looking back at the history of ischemic tolerance, this phenomenon was reported first in the myocardium, and subsequently in the central nervous system. Hereafter, we describe the ischemic tolerance of the brain and spinal cord.

Mechanisms of delayed and rapid ischemic tolerance
--------------------------------------------------

### Brain

Regarding the ischemic tolerance of the brain, there have been many reports of delayed IPC, and its mechanism has also been examined since its discovery.^[@B3],[@B7],[@B8]^ Activation of various receptors and transcription factors, as well as expression of various genes and proteins, are involved in a complicated manner, and exact protective mechanisms are still unknown.^[@B3],[@B7],[@B8]^ However, the current hypothesis is that hypoxic stress, acid stress, and excitatory amino acid stress occur because of moderate ischemia, which results in the activation of transcription factors and the production of genes and proteins that act protectively for neural cells, such as Bcl-2 and Mn-superoxide dismutase (MnSOD).^[@B16],[@B17]^ Furthermore, in a recent study of delayed tolerance, preconditioning with a 30 min middle cerebral artery occlusion (MCAO) reduced cortical and subcortical infarct volume following a 120 min MCAO (test ischemia) 72 h later. This preconditioning-induced neuroprotection disappeared when the mitochondrial ATP-sensitive potassium channels (KATP) channel blocker 5HD (5-hydroxydecanoate) was administered 2 hours before the test ischemia.^[@B18]^ This result suggests a possible involvement of mitochondrial KATP channels in the development of tolerance to focal cerebral ischemia, even if the preconditioning stimuli also produce some cytoprotective protein. Moreover, thousands of genes were screened using microarray analysis, and genes involved in ischemic tolerance were identified. Preconditioning resulted in transcriptional changes for genes involved in suppressing metabolic pathways and immune responses, reducing ion-channel activity, and decreasing blood coagulation.^[@B18]^ After the first non-fatal invasion, it seems that gene expression is reprogrammed so that neurons become responsive to decreased blood flow and oxygen limitation, as seen during hibernation when they are subsequently subjected to lethal invasion.^[@B19]^ As described above, it is becoming clear that ischemic tolerance is not just a case of increased cytoprotective protein levels, as was conventionally thought.

Although many reports have demonstrated that delayed-phase neuroprotection evoked by preconditioning is evident after 1 week or longer, there have only been a few investigations into rapidly induced tolerance.^[@B20]^ Nakamura et al. reported that rapid ischemic tolerance may be mediated through an adenosine A1 receptor-related mechanism in a rat focal ischemic model^[@B21]^; however, many aspects of rapid tolerance are still uncertain. Furthermore, Perez-Pinzon et al.^[@B22]^ recently reported that rapid IPC reduced microglial activation after subsequent cerebral ischemia, suggesting that the beneficial effects of IPC may also involve an anti-inflammatory process.

Spinal cord
-----------

The incidence of neurological deficits after aortic surgery has not changed appreciably over the last 50 years. Both anesthesiologists and vascular surgeons have attempted to resolve this clinically important issue by employing various strategies to prevent ischemic spinal cord injury. Kakimoto et al. used a rabbit model to investigate whether pretreatment with sublethal ischemia of the spinal cord can attenuate neuronal injury after spinal cord ischemia.^[@B6]^ Rapid IPC protects the spinal cord against neuronal damage 24 h, but not 7 days, after reperfusion in a rabbit model of spinal cord ischemia, suggesting that the efficacy of rapid IPC may be transient.^[@B5]^ Mechanisms by which rapid IPC can protect the spinal cord early after ischemic injury are unknown. However, three possible mechanisms are as follows. Firstly, adenosine and adenosine triphosphate-sensitive potassium channels may be involved in the acquisition of ischemic tolerance by rapid IPC, as Nakamura et al. reported in a model of cerebral ischemia.^[@B21]^ Secondly, there may be an involvement of mitochondrial KATP channels in the development of rapid tolerance to spinal cord ischemia. Caparrelli et al. demonstrated that administration of a potent mitochondrial adenosine triphosphate-sensitive potassium channel opener, diazoxide, improved neurologic injury in a model of spinal cord ischemia.^[@B23]^ Thirdly, Fan et al. reported that rapid IPC may enhance the ischemic tolerance of the spinal cord by increasing spinal cord blood flow and decreasing norepinephrine concentration after lethal ischemia.^[@B24]^ Further study is required to clarify the mechanisms of the beneficial effects of rapid IPC on the spinal cord.

Postischemic tolerance (early and delayed)
------------------------------------------

### Brain

IPoC performed immediately or within 30 min after reperfusion is defined as rapid IPoC, whereas that performed hours or days after reperfusion is defined as delayed IPoC^[@B25]^ ([Fig. 1](#F1){ref-type="fig"}). Rapid IPoC has been demonstrated as neuroprotective by Zhao et al. and Gao X et al.^[@B25],[@B26]^ They confirmed that rapid IPoC reduces infarct size when started 10 to 30 s after reperfusion, but does not show any effect if it is started more than 3 min after reperfusion.^[@B25],[@B26]^ This extremely short therapeutic time window of rapid IPoC may hinder its clinical translation.

The exact mechanism of rapid IPoC has not yet been determined, but since rapid IPoC is performed immediately after reperfusion, possible mechanisms may include harmful reactions such as free radical products caused by reperfusion and obstacles to various cell signaling pathways. Duanmu et al. reported that rapid IPoC upregulates acid-sensing ion channel 2a expression in the rat hippocampus after global brain ischemia, which is considered to promote neuronal tolerance to ischemic brain injury.^[@B27]^

In contrast, delayed IPoC is applied a few hours, or even a few days, after reperfusion. In a global ischemia model with induction by 4-vessel occlusion, Burda et al. confirmed that hippocampal neuronal death measured 7 days after global ischemia decreased when delayed IPoC for was performed for 5 min, 2 days after reperfusion.^[@B28]^ Other groups have also confirmed this protective phenomenon in similar global ischemia models.^[@B29]^

Delayed IPoC is thought to regulate the secondary response occurring in the delayed phase after reperfusion injury. For example, it is considered that the mechanism of delayed IPoC involves the attenuation of cerebral blood flow decrease and the inflammatory response occurring late after reperfusion, which is also a delayed adverse event after a stroke.^[@B28]--[@B30]^ In addition, it may promote angiogenesis and neurogenesis. However, it is not known how much the intensification of intrinsic defense mechanisms is involved in the expression of delayed IPoC, and further research is needed.

Spinal cord
-----------

There are several studies into the protective effects of post-conditioning with volatile (inhalation) anesthetics for spinal cord ischemia.^[@B9]^ However, there are no reports of IPoC for ischemic spinal cord injury, possibly because it is difficult to apply clinically because of safety and ethical aspects.

Cross-tolerance
---------------

Ischemic tolerance induced by something other than brief ischemia is called cross-tolerance. After Kitagawa et al. and Kirino et al. demonstrated delayed ischemic tolerance in a gerbil model of global ischemia,^[@B2],[@B3]^ multiple preconditioning stimuli have been reported to induce ischemic tolerance, including hypoxia,^[@B31]^ hyperoxia,^[@B32]^ hypothermia,^[@B33],[@B34]^ hyperthermia,^[@B35],[@B36]^ epidural electrical stimulation,^[@B37]^ lipopolysaccharide (LPS),^[@B38]^ diphosphoryl lipid A (DPL),^[@B39]^ 3-nitropropionate (3-NP),^[@B40]^ cortical spreading depression (CSD),^[@B41],[@B42]^ morphine^[@B43]^ and erythropoietin^[@B44]^ ([Table 2](#T2){ref-type="table"}). The following are representative items in which cross-tolerance was confirmed experimentally, and that are likely to have a clinical application because of their low invasiveness.

###### 

Representative reported items which cross-tolerance was confirmed in brain and spinal cord

                                              Delayed tolerance            Rapid tolerance        Postconditioning
  ---------------- -------------------------- ---------------------------- ---------------------- ------------------
  Brain            Hyperoxygen                Wada K 2001^[@B32]^                                 
  Sevoflurane                                 Codaccioni JL 2009^[@B48]^   Zhang Y 2011^[@B49]^   
  Isoflurane       Xiong L 2003^[@B46]^                                                           
  Xenon            Ma D 2006^[@B47]^                                                              
  Morphine         He Dong 2010^[@B43]^                                                           
  LPS              Tasaki 1997^[@B38]^                                                            
  Erythropoietin   Prass K 2002^[@B44]^                                                           
  CSD              Kobayashi S 1995^[@B41]^   Gniel HM 2011^[@B42]^                               
  3-NPA            Kuroiwa T 2000^[@B40]^                                                         
  DPL              Toyoda T 2000^[@B39]^                                                          
  Hypothermia      Nishio S 2000^[@B33]^      Yunoki M 2002^[@B34]^                               
  Hyperthermia     Xu 2002^[@B36]^            Xu 2002^[@B36]^                                     
                                                                                                  
  Spinal cord      Electrical stimuation      Kakinohara 2005^[@B37]^                             
  Hyperoxygen      Dong H 2002^[@B45]^                                                            
  Hyperthermia                                Zhang P 2000^[@B35]^                                
  Sevoflurene                                 Ding Q 2009^[@B52]^          Wang Q 2011^[@B9]^     
  Isoflurene       Sang H 2006^[@B50]^        Park HP 2005^[@B51]^                                
  Xenon                                                                    Yang YW 2012^[@B53]^   

CSD: Cortical spreading depression, DPL: diphosphoryl lipid A, LPS: lipopolysaccharide, 3-NPA: 3-nitropropionic acid.

a). Hyperoxia
-------------

### Brain

Wada et al. reported that in a gerbil forebrain ischemia model, pretreatment of repeated hyperbaric oxygenation (HBO) of 2 atmospheres absolute (ATA) induced delayed ischemic tolerance. They speculated that protection against mitochondrial alterations after ischemia via MnSOD and/or Bcl-2 expression may be related to the induction of ischemic tolerance by repeated HBO pretreatment.^[@B32]^

Spinal cord
-----------

In a rabbit spinal cord ischemia model, delayed tolerance was demonstrated when HBO at 2.5 ATA, 1 hour per day for 5 days, was used as a pretreatment.^[@B45]^

b). Anesthetics
---------------

### Brain

Delayed preconditioning by isoflurane^[@B46]^ and xenon^[@B47]^ and rapid preconditioning and postconditioning by sevoflurane^[@B48],[@B49]^ are reported to be protective for cerebral ischemic injuries. In a rat MCAO model, there is a dosage-dependent (inhalation concentration) protective effect of isoflurane, inhaled once a day for 5 days until 1 day before ischemia. It is reported that the protective mechanism involves the activation of KATP channels.^[@B46]^

Using a neuronal-glial cell coculture, hippocampal slice culture, and an in vivo model of neonatal asphyxia involving hypoxic-ischemic injury to 7-day-old rats, Ma et al. provided evidence for xenon's preconditioning effect, which may be caused by a phosphorylated cAMP (cyclic adenosine 3′,5′-monophosphate)-response element binding protein (pCREB)-regulated synthesis of proteins that promote survival against neuronal injury.^[@B47]^ Codaccioni et al. demonstrated that sevoflurane preconditioning induces rapid tolerance in a rat transient MCAO model.^[@B48]^ Furthermore, Zhang et al. recently reported that sevoflurane postconditioning may decrease blood and brain oxidative injuries, which in turn may cause tolerance in cerebral ischemia/reperfusion rats.

Spinal cord
-----------

For spinal cord ischemia, there are several studies of the protective effects of volatile (inhalation) anesthetics. Delayed and rapid preconditioning by isoflurane.^[@B50],[@B51]^ rapid preconditioning and postconditioning by sevoflurane,^[@B9],[@B52]^ and postconditioning by xenon^[@B47],[@B53]^ are all reported to be protective for ischemic spinal injury. In one study, rabbits received preconditioning with 3.7% sevoflurane in 96% oxygen for 30 min, and at 1 h after preconditioning the animals were subjected to spinal cord ischemia/reperfusion induced by infrarenal aorta occlusion. Sevoflurane preconditioning induced rapid tolerance to spinal cord ischemia/reperfusion in rabbits, and this tolerance may have been mediated through the activation of extracellular signal-regulated kinase (ERK).^[@B52]^ Using a rabbit spinal cord ischemia model, Wang et al. reported a beneficial effect when 3.7% sevoflurane was inhaled for 10 min from the time of reperfusion following 20 min of spinal cord ischemia.^[@B9]^ An increase in superoxide dismutase and catalase activity was demonstrated as the mechanism for these beneficial effects.

In a rat spinal cord ischemia model, inhalation of 50% xenon (and 50% oxygen) for 60 min immediately after spinal cord ischemia for 20 min resulted in a neuroprotective effect compared with controls. An improvement in the functional score and a decrease in the number of apoptotic cells in the spinal cord anterior horn were confirmed.^[@B53]^ Thus, a number of studies have shown that inhalation anesthetics are effective for spinal cord protection. However, there has been no evidence of these effects in clinical research.

c). Epidural electrical stimulation
-----------------------------------

### Spinal cord

In 2005, Kakinohana et al. confirmed delayed ischemic tolerance of the spinal cord induced by epidural electrical stimulation in a rat transient aortic occlusion model.^[@B37]^ Electrical stimuli on the epidural space surrounding the spinal cord is already an established treatment in pain clinics and can be performed safely. There is no report of cross-tolerance by epidural stimulation in the brain.

d). Hypothermia
---------------

### Brain

Hypothermic preconditioning elicits both delayed and rapid forms of tolerance to focal ischemic injury.^[@B33],[@B34]^ Hypothermia is already an approved clinical procedure for intraischemic and postischemic therapy, and it is therefore possible that hypothermia could be a clinically useful conditioning stimulus to limit injury elicited by anticipated periods of ischemia. There is no report of cross-tolerance by hypothermia in the spinal cord.

Remote tolerance
----------------

Various types of preconditioning stimuli have been used to protect the brain and spinal cord. A disadvantage involved in many preconditioning stimuli is that they may cause damage with only minor changes in their intensity or duration.^[@B7]^ RIPC is a phenomenon in which ischemic tolerance develops in target organs, caused by ischemic injury induced in organs or parts of the body away from the target organ. In RIPC, subthreshold ischemia can be performed more safely by avoiding important organs such as the brain and the heart, and thus a clinical application is more likely than with conventional preconditioning. IPC and postconditioning of the central nervous system were reported 4 and 5 years after IPC and postconditioning of the myocardium were reported, respectively.^[@B1]--[@B3],[@B13],[@B14])^ However, RIPC of the spinal cord was reported more than 10 years after RIPC of the myocardium was reported.^[@B11],[@B54]^ This may mean that the effects of RIPC are difficult to detect in the central nervous system.

Similar to direct IPC, a protective effect of delayed and rapid preconditioning and postconditioning have been reported in RIPC.^[@B12],[@B54]--[@B56]^ Furthermore, in RIPC a subthreshold ischemia during cerebral ischemia is possible, known as perconditioning^[@B12]^ ([Fig. 1](#F1){ref-type="fig"}). For RIPC, the following three mechanisms are considered, (1) a brief ischemic stimulation of distant organs is transmitted to the target organs via the autonomic nervous system; (2) a pathway in which humoral factors such as adenosine are released in remote organs and carried to target organs, or (3) a brief ischemic stimulation of distant organs causes a systemic anti-inflammatory reaction, which in turn increases production of interleukin 10 and suppresses production of Tumor Necrosis Factor α (TNFα), which consequently protects the target organ.^[@B7]^

Brain
-----

Delayed and rapid RIPC have been demonstrated to reduce infarct size in a focal and global ischemia model ([Table 1](#T1){ref-type="table"}). Hahn et al. demonstrated a protective effect of remote perconditioning by transient limb ischemia in a model of regional brain ischemia/reperfusion injury.^[@B12]^ Furthermore, Ren et al. demonstrated that remote postconditioning performed immediately after reperfusion markedly reduces infarct size by rat focal ischemia model.^[@B56]^ In addition, delayed remote postconditioning initiated as late as 3 hours after reperfusion, though not 6 hours, robustly reduces infarct size.^[@B56]^ These results suggest that remote postconditioning provides a wide therapeutic time window for clinical translation.

Spinal Cord
-----------

In the area of remote preconditioning against spinal ischemia, there are only a few studies demonstrating that limb ischemia reduces ischemic spinal injury. Dong et al. studied the effects of limb RIPC in spinal cord ischemia in New Zealand White rabbits. All rabbits were subjected to 20 min of spinal cord ischemia by aortic occlusion. Thirty minutes before the ischemia, rabbits were subjected to sham intervention or RIPC using bilateral femoral artery occlusion. RIPC was confirmed to improve neurologic function and reduced histological damage, which was associated with increased endogenous antioxidant activity.^[@B57]^

Clinical uses of preconditioning
--------------------------------

### Brain

The effects of IPC on cerebral and myocardial infarction have not been fully investigated because they cannot be predicted based on their nature. The effects of IPC have therefore been mainly studied for cardiovascular surgery, with studies designed to compare prognosis and complications. Although some studies showed effectiveness of IPC, others showed ineffectiveness; the effect of IPC on human myocardium is inconsistent.^[@B58]--[@B60]^ In the brain, there have also been studies comparing prognosis and complications using IPC for carotid endarterectomy, but there are relatively few reports compared to those of cardiovascular surgery^[@B60],[@B61]^ The lack of studies is mainly because causing ischemia in a brain with a high risk of cerebral infarction is dangerous. Nevertheless, a retrospective study revealed that patients that have a transient cerebral ischemic attack (TIA) before cerebral infarction had better prognosis after cerebral infarction than patients who did not have a TIA.^[@B62],[@B63]^ It is therefore thought that ischemic tolerance occurs in humans if the conditions match well. The effectiveness of RIPC, a procedure that resolves the risk of causing cerebral infarction by preconditioning stimuli, was first reported in the human brain in 2012.^[@B64]^ This study aimed to evaluate the preventive effect of short-term repetitive RIPC on the recurrence of stroke in symptomatic atherosclerotic intracranial artery stenosis (IAS) patients. In this study, 103 cerebral ischemia patients with high-risk vascular stenosis within 30 days of onset were divided into two groups (a control and an RIPC group). In the RIPC group, patients received brief ischemia and reperfusion of the bilateral upper limbs 5 times. This procedure was performed twice a day for 300 consecutive days and the incidence of recurrent stroke was compared with the control group.

In the control group, the recurrence rate of stroke was 23.3% and 26.7% at 90 days and 300 days, respectively. In the RIPC group, the incidence of recurrent stroke dropped to 5% and 7.9% at 90 days and 300 days (*P* \< 0.01), respectively.^[@B64]^

In recent years, the concept of IPC has been applied to prevent secondary damage at the site of acute treatment of stroke.^[@B65]--[@B70]^ For example, it was recently reported that in patients receiving thrombolysis in the acute phase of stroke, the survival rate 1 month after onset increased when RIPC was performed during transport to the hospital.^[@B68]^ Delayed cerebral ischemia (DCI) occurs due to vasospasm after a subarachnoid hemorrhage (SAH), and this may be a situation that is suitable for confirming the effects of IPC clinically.^[@B71],[@B72]^ It is reported that in patients receiving RIPC after a subarachnoid hemorrhage, the mean velocity of the middle cerebral artery decreased, the ratio of lactic acid:pyruvic acid decreased, and the glycerol level decreased, and these effects lasted up to 2 days.^[@B73]^

As treatment of unruptured aneurysms, such as clipping and coil embolization, may cause brain damage by transient arterial occlusion, for example, this is also considered to be a suitable medical situation for examining the effect of RIPC clinically. Tulu et al. investigated whether RIPC before treatment of an unruptured aneurysm alleviates brain damage, by measuring serum biomarkers or performing brain magnetic resonance imaging (MRI) after surgery. The results of this trial, however, did not give a clear answer as to whether RIPC before treatment of unruptured aneurysms is useful for protecting the brain from ischemia.^[@B70]^

Spinal cord
-----------

As mentioned previously, RIPC may protect the spinal cord from ischemic injury; however, there are only a few studies that have investigated whether preconditioning reduces ischemic spinal injury. Hu et al. conducted a randomized clinical trial to assess the effect of RIPC on neurologic outcome in patients undergoing spine surgery. Forty patients with cervical myelopathy who underwent selective decompression surgery were divided into either an RIPC group (*n* = 20) or a control group (*n* = 20) and the therapeutic effect was investigated. Recovery rate after surgery was better in the RIPC group than in the control group (*P* \< 0.05).^[@B69]^

Summary of current status of research for spinal cord ischemic tolerance
------------------------------------------------------------------------

Spinal cord ischemic tolerance induced by rapid IPC, delayed IPC, and rapid RIPC has been reported from between several years to 10 years after it was reported in the brain.^[@B5],[@B6],[@B57]^ However, no experimental reports of IPoC, RIPoC, or ROPerC have been confirmed in the spinal cord, and we think they are worth examining in the future ([Table 1](#T1){ref-type="table"}). Clinically, tolerance induced by RIPC is considered useful particularly for the spinal cord. A clinical trial confirmed the usefulness of RIPC in spinal surgery^[@B69]^; however, the number of clinical trials for spinal diseases is few compared with that of cerebral diseases.^[@B60]--[@B73]^ Clinical trials should thus be further promoted, including for procedures that are thought to be more clinically useful, such as RIPoC and RIPerC. With respect to cross tolerance, there are many reports of spinal cord tolerance induced by inhalation anesthetics compared with similar reports in the brain.^[@B9],[@B50]--[@B53]^ It is important for physicians performing spinal cord surgery to summarize and understand such knowledge.

Conclusion
==========

This review of the literature has summarized current knowledge of the ischemic tolerance of the brain and spinal cord. One drawback of preconditioning stimuli is that they are also capable of producing injury with only minor changes in their intensity or duration. However, IPoC and RIPC have been reported to be neuroprotective, and the possibility of clinical applications is expanding.

Further experimental or clinical research into the use of conditioning methods to induce spinal cord tolerance, such as RIPerC and RIPoC, are especially necessary because these methods are considered clinically useful, but currently have insufficient reported evidence to support their use.
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